The stock is likely to react positively to the raised guidance and strong PBP channel growth, despite the sequential decline in new patient starts. Monitor management's commentary on patient start trends during the earnings call for further clarity on demand sustainability.
Price Chart
Executive Summary
Beta Bionics reported strong Q1 2026 revenue growth of 57% year-over-year and raised full-year 2026 guidance for revenue, PBP channel penetration, and gross margin. Despite a sequential decline in new patient starts, the stock is likely to react positively due to the raised outlook and accelerating PBP channel growth.
Key Financial Metrics
Key Facts
- Q1 2026 net sales of $27.6M, up 57% YoY
- PBP channel sales up 181% YoY to $10.7M
- Gross margin improved 864 bps YoY to 59.5%
- Raised full-year 2026 revenue guidance to $131M–$136M (from $130M–$135M)
- New patient starts declined sequentially by 10–20%
Financial Impact
Revenue beat consensus by $0.6M; raised full-year guidance signals accelerating commercial execution
Risk Factors
- Sequential decline in new patient starts may raise concerns about near-term demand
- Net loss widened to $21.9M despite revenue growth, indicating ongoing profitability challenges
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-002614 |
| Document: f8k_042126.htm | 0001171843-26-002614 |
| Document: 0001171843-26-002614-index-headers.html | 0001171843-26-002614 |
| Document: 0001171843-26-002614-index.html | 0001171843-26-002614 |
| Document: 0001171843-26-002614.txt | 0001171843-26-002614 |
| 8-K Data (Synthetic) | 0001171843-26-002614 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 19d ago | SC 13G | $18.08 | awaiting T+20 | — | $22.13 (+22.40%) |
Sep 23, 2026 4w ago | Insider Cluster | $21.76 $19.34 | ▲ +11.12% | ▲ +10.70% | $22.13 (−1.70%) |
Sep 18, 2026 5w ago | Insider Cluster | $22.04 $16.84 | ▲ +23.59% | ▲ +22.69% | $22.13 (−0.41%) |
Sep 17, 2026 5w ago | Press Release | $21.89 $16.35 | ▼ −25.31% | ▼ −25.51% | $22.13 (+1.10%) |
Sep 17, 2026 5w ago | Insider Cluster | $21.89 $16.35 | ▼ −25.31% | ▼ −25.51% | $22.13 (+1.10%) |
Sep 15, 2026 5w ago | Press Release | $22.18 $16.87 | ▲ +23.94% | ▲ +26.00% | $22.13 (+0.23%) |
Sep 15, 2026 5w ago | 8-K | $22.18 $16.87 | ▼ −23.94% | ▼ −26.00% | $22.13 (−0.23%) |
Sep 15, 2026 5w ago | Press Release | $22.18 $16.87 | ▲ +23.94% | ▲ +26.00% | $22.13 (+0.23%) |
Sep 14, 2026 6w ago | Press Release | $16.73 $17.86 | ▲ +6.75% | ▲ +4.49% | $22.13 (+32.28%) |
Sep 10, 2026 6w ago | Insider Cluster | $16.57 $17.63 | ▼ −6.40% | ▼ −4.53% | $22.13 (−33.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers